Impact on antiviral resistance of E119V, I222L and R292K substitutions in influenza A viruses bearing a group 2 neuraminidase (N2, N3, N6, N7 and N9)

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 11, 2016, Pages 3036-3045

  Gaymard, Alexandre ^a,b   Charles Dufant, Aymeric ^a   Sabatier, Murielle ^a   Cortay, Jean Claude ^a   Frobert, Emilie ^a,b   Picard, Caroline ^a   Casalegno, Jean Sébastien ^a,b   Rosa Calatrava, Manuel ^a   Ferraris, Olivier ^a   Valette, Martine ^a,b   Ottmann, Michèle ^a   Lina, Bruno ^a,b   Escuret, Vanessa ^a,b  

^a UNIVERSITÉ LYON 1   (France)

^b HOSPICES CIVILS DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; LANINAMIVIR; OSELTAMIVIR; SIALIDASE INHIBITOR; VIRUS SIALIDASE; ZANAMIVIR; ANTIVIRUS AGENT; SIALIDASE;

ANIMAL CELL; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; BINDING AFFINITY; GENETIC REASSORTMENT; GENETIC VARIABILITY; IC50; IN VITRO STUDY; INFLUENZA A VIRUS; MDCK CELL LINE; MUTATIONAL ANALYSIS; NONHUMAN; REVERSE GENETICS; VIRUS CELL INTERACTION; VIRUS INHIBITION; DRUG EFFECTS; GENETICS; HUMAN; MISSENSE MUTATION;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HUMANS; INFLUENZA A VIRUS; MUTATION, MISSENSE; NEURAMINIDASE; OSELTAMIVIR; REASSORTANT VIRUSES; REVERSE GENETICS;

EID: 84994495717     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw275     Document Type: Article

References (54)

1. Skehel JJ, Wiley DC. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 2000; 69: 531-69.
2. Air GM. Influenza neuraminidase. Influenza Other Respir Viruses 2012; 6: 245-56.
3. Russell RJ, Haire LF, Stevens DJ et al. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 2006; 443: 45-9.
4. Colman PM, Varghese JN, Laver WG. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 1983; 303: 41-4.
5. Colman PM, Hoyne PA, Lawrence MC. Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase. J Virol 1993; 67: 2972-80.
6. WHO. WHO Guidelines for Pharmacological Management of Pandemic Influenza A(H1N1) 2009 and Other Influenza Viruses. 2010. http://www.who.int/csr/resources/publications/swineflu/h1n1_guidelines_ pharmaceutical_mngt.pdf.
7. Von Itzstein M. Thewar against influenza: discovery and development of sialidase inhibitors. Nat Rev Drug Discov 2007; 6: 967-74.
8. Baz M, Abed Y, McDonald J et al. Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin Infect Dis 2006; 43: 1555-61.
9. Ison MG, Gubareva LV, Atmar RL et al. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis 2006; 193: 760-4.
10. Kiso M, Mitamura K, Sakai-Tagawa Y et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004; 364: 759-65.
11. Okomo-Adhiambo M, Demmler-Harrison GJ, Deyde VM et al. Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. Antimicrob Agents Chemother 2010; 54: 1834-41.
12. Tamura D, Sugaya N, Ozawa M et al. Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors. Clin Infect Dis 2011; 52: 432-7.
13. Richard M, Deléage C, Barthélémy M et al. Impact of influenza A virus neuraminidase mutations on the stability, activity, and sensibility of the neuraminidase to neuraminidase inhibitors. J Clin Virol 2008; 41: 20-4.
14. Escuret V, Collins PJ, Casalegno J-S et al. A novel I221L substitution in neuraminidase confers high-level resistance to oseltamivir in influenza B viruses. J Infect Dis 2014; 210: 1260-9.
15. Richard M, Ferraris O, Erny A et al. Combinatorial effect of two framework mutations (E119V and I222L) in the neuraminidase active site of H3N2 influenza virus on resistance to oseltamivir. Antimicrob Agents Chemother 2011; 55: 2942-52.
16. Gao H-N, Lu H-Z, Cao B et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med 2013; 368: 2277-85.
17. Marjuki H, Mishin VP, Chesnokov AP et al. Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivirtreated patient in Taiwan. J Infect Dis 2015; 211: 249-57.
18. Richard M, Erny A, Caré B et al. Rescue of a H3N2 influenza virus containing a deficient neuraminidase protein by a hemagglutinin with a low receptor-binding affinity. PLoS One 2012; 7: e33880.
19. Hoffmann E, Stech J, Guan Y, et al. Universal primer set for the full-length amplification of all influenza A viruses. Arch Virol 2001; 146: 2275-89.
20. Ferraris O, Kessler N, Lina B. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice. Antiviral Res 2005; 68: 43-8.
21. WHO. Meetings of theWHOWorking Group on Surveillance of Influenza Antiviral Susceptibility -Geneva, November 2011 and June 2012. Relevé Épidémiologique Hebd Sect Hygiène Secrétariat Société Nations Wkly Epidemiol Rec Health Sect Secr Leag Nations 2012; 87: 369-74.
22. Casalegno J-S, Bouscambert-Duchamp M, Caro V et al. Oseltamivirresistant influenza A(H1N1) viruses in south of France, 2007/2009. Antiviral Res 2010; 87: 242-8.
23. Rameix-Welti M-A, Enouf V, Cuvelier F et al. Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir. PLoS Pathog 2008; 4: e1000103.
24. Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. Am J Epidemiol 1938; 27: 493-7.
25. Song M-S, Marathe BM, Kumar G et al. Unique determinants of neuraminidase inhibitor resistance among N3, N7, and N9 avian influenza viruses. J Virol 2015; 89: 10891-900.
26. Li Q, Qi J,Wu Y, et al. Functional and structural analysis of influenza virus neuraminidase N3 offers further insight into the mechanisms of oseltamivir resistance. J Virol 2013; 87: 10016-24.
27. Stoner TD, Krauss S, Turner JCM et al. Susceptibility of avian influenza viruses of the N6 subtype to the neuraminidase inhibitor oseltamivir. Antiviral Res 2012; 93: 322-9.
28. Sun X, Li Q, Wu Y et al. Structure of influenza virus N7: the last piece of the neuraminidase 'jigsaw' puzzle. J Virol 2014; 88: 9197-207.
29. Gao HN, Yao HP, Liang WF et al. Viral genome and antiviral drug sensitivity analysis of two patients from a family cluster caused by the influenza A(H7N9) virus in Zhejiang, China, 2013. Int J Infect Dis 2014; 29: 254-8.
30. Moulès V, Terrier O, Yver M et al. Importance of viral genomic composition in modulating glycoprotein content on the surface of influenza virus particles. Virology 2011; 414: 51-62.
31. Carr J, Ives J, Kelly L et al. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Res 2002; 54: 79-88.
32. Herlocher ML, Carr J, Ives J et al. Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antiviral Res 2002; 54: 99-111.
33. Yen H-L, Herlocher LM, Hoffmann E et al. Neuraminidase inhibitorresistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob Agents Chemother 2005; 49: 4075-84.
34. Hu Y, Lu S, Song Z et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 2013; 381: 2273-9.
35. Yen H-L, McKimm-Breschkin JL, Choy K-T, et al. Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population. mBio 2013; 4: e00396-13.
36. Wu Y, Bi Y, Vavricka CJ et al. Characterization of two distinct neuraminidases from avian-origin human-infecting H7N9 influenza viruses. Cell Res 2013; 23: 1347-55.
37. Sleeman K, Guo Z, Barnes J et al. R292K substitution and drug susceptibility of influenza A(H7N9) viruses. Emerg Infect Dis 2013; 19: 1521-4.
38. Abed Y, Baz M, Boivin G. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antivir Ther 2006; 11: 971-6.
39. Simon P, Holder BP, Bouhy X et al. The I222V neuraminidase mutation has a compensatory role in replication of an oseltamivir-resistant influenza virus A/H3N2 E119V mutant. J Clin Microbiol 2011; 49: 715-7.
40. Zürcher T, Yates PJ, Daly J et al. Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro. J Antimicrob Chemother 2006; 58: 723-32.
41. Takashita E, Meijer A, Lackenby A et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014. Antiviral Res 2015; 117: 27-38.
42. Bouvier NM, Lowen AC, Palese P. Oseltamivir-resistant influenza A viruses are transmitted efficiently among guinea pigs by direct contact but not by aerosol. J Virol 2008; 82: 10052-8.
43. Roussy J-F, Abed Y, Bouhy X et al. Emergence of an oseltamivirresistant influenza A/H3N2 virus in an elderly patient receiving a suboptimal dose of antiviral prophylaxis. J Clin Microbiol 2013; 51: 4234-6.
44. Herlocher ML, Truscon R, Elias S et al. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis 2004; 190: 1627-30.
45. Achenbach JE, Bowen RA. Effect of oseltamivir carboxylate consumption on emergence of drug-resistant H5N2 avian influenza virus in mallard ducks. Antimicrob Agents Chemother 2013; 57: 2171-81.
46. Orozovic G, Orozovic K, Järhult JD et al. Study of oseltamivir and zanamivir resistance-related mutations in influenza viruses isolated from wild mallards in Sweden. PLoS One 2014; 9: e89306.
47. Pizzorno A, Bouhy X, Abed Y et al. Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors. J Infect Dis 2011; 203: 25-31.
48. Boltz DA, Douangngeun B, Phommachanh P et al. Emergence of H5N1 avian influenza viruses with reduced sensitivity to neuraminidase inhibitors and novel reassortants in Lao People's Democratic Republic. J Gen Virol 2010; 91: 949-59.
49. Hurt AC, Holien JK, Barr IG. In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. Antimicrob Agents Chemother 2009; 53: 4433-40.
50. Pizzorno A, Abed Y, Bouhy X et al. Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus. Antimicrob Agents Chemother 2012; 56: 1208-14.
51. Govorkova EA, Ilyushina NA, Marathe BM et al. Competitive fitness of oseltamivir-sensitive and-resistant highly pathogenic H5N1 influenza viruses in a ferret model. J Virol 2010; 84: 8042-50.
52. Itoh Y, Shichinohe S, Nakayama M et al. Emergence of H7N9 influenza A virus resistant to neuraminidase inhibitors in nonhuman primates. Antimicrob Agents Chemother 2015; 59: 4962-73.
53. Furuta Y, Gowen BB, Takahashi K et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 2013; 100: 446-54.
54. L'Huillier AG, Abed Y, Petty TJ et al. The E119D neuraminidase mutation confers pan-resistance to neuraminidase inhibitors in an A(H1N1)pdm09 isolate from a stem-cell transplant recipient. J Infect Dis 2015; 212: 1726-34